Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6168MR)

This product GTTS-WQ6168MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6168MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4370MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ2877MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ13998MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ7314MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ973MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ15242MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ9144MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ10279MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFG 316
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW